Millennium Management Acquires 5.1% Passive Stake in SAB Biotherapeutics

On May 1, 2026, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander jointly filed a Schedule 13G disclosing a new passive ownership stake in SAB Biotherapeutics, Inc. (SABS). The filing indicates that the reporting persons collectively beneficially own 3,432,153 shares of Common Stock, representing 5.1% of the company's outstanding shares. This position was established as of April 24, 2026. The shares are held by entities subject to voting and investment control by Millennium Management LLC, with Israel A. Englander serving as the sole voting trustee of the managing member of Millennium Group Management LLC. The filing was made under Rule 13d-1(c), certifying that the acquisition was not intended to influence or change the control of the issuer. The calculation of the ownership percentage is based on 66,934,576 shares outstanding as of March 17, 2026. This represents a significant new institutional holding for the clinical-stage biopharmaceutical company.